



# incircular

Stabilized proteins for biopharma applications

---

Dr. Saskia Neubacher  
CEO

Dutch Life Science Conference 2023

# OUR MISSION



Advanced proteins for biopharma



Founded in 2021

by



Patent filed  
2 technology

*1st US patent granted*

effective stabilization using our unique & proprietary technology



2.8 M€ funding raised  
EIC Transition  
5 employees



**Funded by  
the European Union**

Funded under Horizon Europe framework – EIC Transition project INCYPRonext (Ref: 101057978 — HORIZON-EIC-2021-TRANSITIONOPEN-01) during the period 06/2022 – 05/2025.



# OUR TEAM

---

Scientist & business co-inventors/founders  
and a skilled team



Dr. Saskia Neubacher  
*CEO*



Dr. Wil Hazenberg  
*BD advisor*



Prof. Tom Grossmann  
*Scientific advisor*



Dr. Sven Hennig  
*Scientific advisor*



Dr. Marcelo  
Masman  
*Comp. Biochemistry*



Dr. George  
Hutchins  
*Protein Engineering*



Dr. David  
Hamilton  
*Chemistry*





Sharmila  
Srinivasan  
*Molecular Biology*



Lorenzo  
Valino  
*Molecular Biology*


# OUR PROPRIETARY TECHNOLOGY

- ✓ Efficient design
- ✓ Minimal modification
- ✓ Retained structure & function
- ✓ High thermal stability






# INCYPRO BENEFITS




Reduced aggregation




Extreme longevity

Locked protein complexes




Stabilized membrane proteins




# OUR ADVANTAGE

## Technology comparison

	 incircular INCYPRO	Directed Evolution	Comp. Seq. Optimization	Specific Polar Modification	Non-specific Polar Modif.	Fusion & Tags
Modification	●	○	○	●	○	○
Effectiveness	●	●	○	○	○	○
Multimer stabilization	●	○	○	○	○	●
Aggregation	●	○	●	○	●	○

**Important advantage:** INCYPRO can be combined with the other technologies.

# THERAPEUTIC PROTEIN MARKET OPPORTUNITY



# ASPARAGINASE


therapeutic protein  
treatment of acute  
lymphoblastic leukemia (ALL)

Major problems:

- ✗ aggregation
- ✗ immunogenicity


> increased stability <

thermal




> prolonged activity <

shelf life




stable complex



2.3 Å cryoEM  
of ICR-E302 with

ThermoFisher  
SCIENTIFIC

temperature













# GROWING PORTFOLIO

---

Incircular is developing stabilized proteins for various applications in collaboration with partners

		Asparaginase	Potential biobetter for treatment of acute lymphoblastic leukemia (ALL)
	 Amsterdam UMC	Galectin	Immuno-modulator for potential use in rheumatoid arthritis (RA)
	 large pharma	GPCR	Receptor for drug discovery
		Protease	Potential antibiotic for use against MDR <i>Staphylococcus</i>
	 biotech	Additional candidates	Ongoing discussions with two potential partners

# BUSINESS MODEL

---

Incircular will leverage its **technology platform** to build a **portfolio of stabilized proteins** through partnerships and in-house development

## Partnerships



## In-house development of therapeutic proteins



Goal is to become a **profitable & diversified biotech company**

# PERSPECTIVE

